Clinical Trials Browser

NIH × Interventional × obatoclax × Clear all

NCT00521144 2015-05-05

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

Phase 1/2 Completed

22 enrolled 9 charts

Thoracic

Small Cell Lung Carcinoma

NCT00719901 2015-01-12

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Phase 1 Terminated

22 enrolled

DermatologicLymphoidOther hematologic neoplasmSarcoma

Blast Crisis, Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT00612612 2013-09-30

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 1 Terminated

28 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT01238146 2013-06-06

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell